FULC
Fulcrum Therapeutics·NASDAQ
--
--(--)
--
--(--)
4.54 / 10
Netural
Fulcrum Therapeutics' fundamental score is moderate (4.5/10). Key positives include strong year-over-year revenue growth (Total Operating Revenue +78.47% YoY, Operating Revenue +92.66% YoY) and a healthy interest-coverage ratio (15.48%), indicating solid operating cash generation. However, elevated Days Sales Outstanding (72.55) suggests potential collection inefficiencies, and the PB-ROE factor (1.26) hints at sub-optimal asset efficiency. These mixed signals result in a neutral fundamental rating.
Analysis Checks(8/10)
Revenue-MV
Value-0.26
Score3/3
Weight17.37%
1M Return10.54%
Value-0.26
Score3/3
Weight17.37%
1M Return10.54%
Days sales outstanding
Value72.55
Score1/3
Weight-1.91%
1M Return-1.57%
Value72.55
Score1/3
Weight-1.91%
1M Return-1.57%
Net income-Revenue
Value-0.17
Score2/3
Weight13.86%
1M Return8.45%
Value-0.17
Score2/3
Weight13.86%
1M Return8.45%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-1.39%
1M Return-1.11%
Value15.48
Score2/3
Weight-1.39%
1M Return-1.11%
Asset-MV
Value-0.50
Score3/3
Weight25.68%
1M Return13.15%
Value-0.50
Score3/3
Weight25.68%
1M Return13.15%
Total operating revenue (YoY growth rate %)
Value78.47
Score2/3
Weight1.48%
1M Return1.11%
Value78.47
Score2/3
Weight1.48%
1M Return1.11%
Profit-MV
Value0.46
Score2/3
Weight13.85%
1M Return8.45%
Value0.46
Score2/3
Weight13.85%
1M Return8.45%
PB-ROE
Value1.26
Score1/3
Weight16.86%
1M Return9.57%
Value1.26
Score1/3
Weight16.86%
1M Return9.57%
Operating revenue (YoY growth rate %)
Value92.66
Score2/3
Weight0.57%
1M Return0.43%
Value92.66
Score2/3
Weight0.57%
1M Return0.43%
Cash-MV
Value-0.07
Score2/3
Weight13.62%
1M Return8.41%
Value-0.07
Score2/3
Weight13.62%
1M Return8.41%
Revenue-MV
Value-0.26
Score3/3
Weight17.37%
1M Return10.54%
Value-0.26
Score3/3
Weight17.37%
1M Return10.54%
Total operating revenue (YoY growth rate %)
Value78.47
Score2/3
Weight1.48%
1M Return1.11%
Value78.47
Score2/3
Weight1.48%
1M Return1.11%
Days sales outstanding
Value72.55
Score1/3
Weight-1.91%
1M Return-1.57%
Value72.55
Score1/3
Weight-1.91%
1M Return-1.57%
Profit-MV
Value0.46
Score2/3
Weight13.85%
1M Return8.45%
Value0.46
Score2/3
Weight13.85%
1M Return8.45%
Net income-Revenue
Value-0.17
Score2/3
Weight13.86%
1M Return8.45%
Value-0.17
Score2/3
Weight13.86%
1M Return8.45%
PB-ROE
Value1.26
Score1/3
Weight16.86%
1M Return9.57%
Value1.26
Score1/3
Weight16.86%
1M Return9.57%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-1.39%
1M Return-1.11%
Value15.48
Score2/3
Weight-1.39%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value92.66
Score2/3
Weight0.57%
1M Return0.43%
Value92.66
Score2/3
Weight0.57%
1M Return0.43%
Asset-MV
Value-0.50
Score3/3
Weight25.68%
1M Return13.15%
Value-0.50
Score3/3
Weight25.68%
1M Return13.15%
Cash-MV
Value-0.07
Score2/3
Weight13.62%
1M Return8.41%
Value-0.07
Score2/3
Weight13.62%
1M Return8.41%
Is FULC undervalued or overvalued?
- FULC scores 4.54/10 on fundamentals and holds a Fair valuation at present. Backed by its -24.71% ROE, 0.00% net margin, -7.41 P/E ratio, 2.66 P/B ratio, and -293.10% earnings growth, these metrics solidify its Netural investment rating.
